BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:18 PM
 | 
Oct 09, 2012
 |  BC Extra  |  Clinical News

BioLineRx gains on updated BL-1020 data

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) gained $0.32 (11%) to $3.35 on Tuesday after reporting updated data from the Phase IIb EAGLE trial of BL-1020 to treat schizophrenia. A new analysis of a subset of patients for whom the time of day...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >